Myositis Pipeline 2026: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Myositis pipeline constitutes 40+ key companies continuously working towards developing 45+ Myositis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Myositis Pipeline Insight, 2026" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Myositis Market.

The Myositis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Get a Free Sample PDF Report to know more about Myositis Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/myositis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gaurav

Some of the key takeaways from the Myositis Pipeline Report:
• Companies across the globe are diligently working toward developing novel Myositis treatment therapies with a considerable amount of success over the years.
• Myositis companies working in the treatment market are JN Biosciences, ImmunoForge, Paean Biotechnology Inc., Merck KGaA, and others, are developing therapies for the Myositis treatment
• Emerging Myositis therapies in the different phases of clinical trials are- HuABC2, PF1801, PN-101, M5049, and others are expected to have a significant impact on the Myositis market in the coming years.
• In April 2025, Calibr-Skaggs Institute for Innovative Medicines, the drug discovery arm of Scripps Research, announced that the FDA has approved its investigational new drug (IND) application to evaluate its switchable chimeric antigen receptor T-cell (sCAR-T) therapy, CLBR001 in combination with SWI019, in patients with autoimmune diseases. Enrollment for the Phase I clinical trial (NCT06913608) is expected to begin shortly. The study will assess the safety and preliminary efficacy of the therapy in conditions such as myositis, systemic sclerosis, lupus, and rheumatoid arthritis, with the possibility of expanding into additional indications. The sCAR-T platform is designed to minimize side effects and reduce patient burden by avoiding the intensive lymphodepletion typically required with conventional CAR-T therapies, addressing a key concern for both patients and rheumatology specialists.
• In March 2025, Abcuro, Inc., a clinical-stage biotech firm focused on treating autoimmune diseases and cancer by precisely targeting cytotoxic T cells, announced it will present safety, pharmacokinetic, and pharmacodynamic findings from its Phase 1 clinical trial of ulviprubart (ABC008) for inclusion body myositis (IBM) at the upcoming American Academy of Neurology (AAN) Annual Meeting.
• In February 2025, Abcuro secured $200 million in Series C funding to advance the development of its first-in-class therapy for inclusion body myositis. The funding will support the completion of the registrational Phase 2/3 MUSCLE trial evaluating ulviprubart, as well as the preparation for its Biologics License Application (BLA) submission and eventual commercial launch.
• In November 2024, argenx has chosen to advance the development of efgartigimod SC (efgartigimod alfa and hyaluronidase-qvfc) in the ongoing Phase 2/3 ALKIVIA trial for adults with idiopathic inflammatory myopathies. This decision follows positive topline results from the Phase 2 segment, where the study met its primary endpoint by showing a statistically significant improvement in the mean total improvement score (TIS) at Week 24. Moreover, efgartigimod SC demonstrated favorable outcomes across all six core TIS measures compared to placebo.

Myositis Overview
Myositis is a rare autoimmune disease characterized by inflammation and weakness of the skeletal muscles, particularly those closest to the trunk of the body. It is classified as an idiopathic inflammatory myopathy, meaning that its exact cause is unknown. However, it is believed to involve an abnormal immune response in which the body's immune system mistakenly attacks its own muscles.

Explore the latest Myositis pipeline insights 2026, including emerging therapies, clinical trials, and market opportunities. Stay ahead in Myositis Clinical Trials
https://www.delveinsight.com/sample-request/myositis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gaurav

Emerging Myositis Drugs Under Different Phases of Clinical Development Include:
• HuABC2: JN Biosciences
• PF1801: ImmunoForge
• PN-101: Paean Biotechnology Inc.
• M5049: Merck KGaA

Myositis Route of Administration
Myositis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Inhalation
• Inhalation/Intravenous/Oral
• Intranasal
• Intravenous
• Intravenous/ Subcutaneous
• NA
• Oral
• Oral/intranasal/subcutaneous
• Parenteral
• Subcutaneous

Myositis Molecule Type
Myositis Products have been categorized under various Molecule types, such as
• Antibody
• Antisense oligonucleotides
• Immunotherapy
• Monoclonal antibody
• Peptides
• Protein
• Recombinant protein
• Small molecule
• Stem Cell
• Vaccine

Myositis Pipeline Therapeutics Assessment
• Myositis Assessment by Product Type
• Myositis By Stage and Product Type
• Myositis Assessment by Route of Administration
• Myositis By Stage and Route of Administration
• Myositis Assessment by Molecule Type
• Myositis by Stage and Molecule Type

DelveInsight's Myositis Report covers around 45+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Myositis product details are provided in the report. Download the Myositis pipeline report to learn more about the emerging Myositis therapies
https://www.delveinsight.com/sample-request/myositis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gaurav

Some of the key companies in the Myositis Therapeutics Market include:
Key companies developing therapies for Myositis are - F. Hoffmann-La Roche Ltd, Pfizer Inc, Zydus Group, Lupin, Bausch Health Companies Inc., Accord Healthcare, Genentech, Inc, Johnson & Johnson Services, Inc., Novartis AG, Endo International Inc, Teva Pharmaceutical Industries Ltd, Glenmark Pharmaceuticals Ltd, Cipla Inc, Dr Reddy's Laboratories Ltd, Abbott, Bristol-Myers Squibb Company, GSK plc, Merz Pharma, Akorn, Incorporated, and others.

Myositis Pipeline Analysis:
The Myositis pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Myositis with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Myositis Treatment.
• Myositis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Myositis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Myositis market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Myositis drugs and therapies
https://www.delveinsight.com/sample-request/myositis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gaurav

Myositis Pipeline Market Drivers
• Growing cases of chronic muscle inflammation, continuous advancement in technology, increased injuries of muscle are some of the important factors that are fueling the Myositis Market.

Myositis Pipeline Market Barriers
• However, high cost of drugs, lack of approved therapies and other factors are creating obstacles in the Myositis Market growth.

Scope of Myositis Pipeline Drug Insight
• Coverage: Global
• Key Myositis Companies: JN Biosciences, ImmunoForge, Paean Biotechnology Inc., Merck KGaA, and others
• Key Myositis Therapies: HuABC2, PF1801, PN-101, M5049, and others
• Myositis Therapeutic Assessment: Myositis current marketed and Myositis emerging therapies
• Myositis Market Dynamics: Myositis market drivers and Myositis market barriers

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.